- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1865-5076
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
CDK4/6 inhibition in luminal breast cancer ; day:20 ; month:6 ; year:2016 ; pages:1-6
Magazine of European Medical Oncology ; (20.6.2016), 1-6
- Creator
-
Gampenrieder, Simon Peter
- Contributor
-
Rinnerthaler, Gabriel
Greil, Richard
SpringerLink (Online service)
- DOI
-
10.1007/s12254-016-0268-2
- URN
-
urn:nbn:de:1111-201606223086
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:02 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Gampenrieder, Simon Peter
- Rinnerthaler, Gabriel
- Greil, Richard
- SpringerLink (Online service)
Other Objects (12)
Proteomic characterisation of triple negative breast cancer cells following CDK4/6 inhibition
Targeting the BRD4/FOXO3a/CDK6 axis sensitizes AKT inhibition in luminal breast cancer
Inhibition of GPX4 enhances CDK4/6 inhibitor and endocrine therapy activity in breast cancer
MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer
Silencing CDK4 radiosensitizes breast cancer cells by promoting apoptosis
FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1
TEX19 increases the levels of CDK4 and promotes breast cancer by disrupting SKP2-mediated CDK4 ubiquitination
Position paper on CDK4/6 inhibitors in early breast cancer
Translational Highlights in Breast and Ovarian Cancer 2019 – Immunotherapy, DNA Repair, PI3K Inhibition and CDK4/6 Therapy
Inhibition of proliferation and migration of luminal and claudin-low breast cancer cells by PDGFR inhibitors
GRHL2-controlled gene expression networks in luminal breast cancer
Prognostic parameters of luminal A and luminal B intrinsic breast cancer subtypes of Pakistani patients
Proteomic characterisation of triple negative breast cancer cells following CDK4/6 inhibition
Targeting the BRD4/FOXO3a/CDK6 axis sensitizes AKT inhibition in luminal breast cancer
Inhibition of GPX4 enhances CDK4/6 inhibitor and endocrine therapy activity in breast cancer
MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer
Silencing CDK4 radiosensitizes breast cancer cells by promoting apoptosis
FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1
TEX19 increases the levels of CDK4 and promotes breast cancer by disrupting SKP2-mediated CDK4 ubiquitination
Position paper on CDK4/6 inhibitors in early breast cancer
Translational Highlights in Breast and Ovarian Cancer 2019 – Immunotherapy, DNA Repair, PI3K Inhibition and CDK4/6 Therapy
Inhibition of proliferation and migration of luminal and claudin-low breast cancer cells by PDGFR inhibitors
GRHL2-controlled gene expression networks in luminal breast cancer
Prognostic parameters of luminal A and luminal B intrinsic breast cancer subtypes of Pakistani patients
Proteomic characterisation of triple negative breast cancer cells following CDK4/6 inhibition
Targeting the BRD4/FOXO3a/CDK6 axis sensitizes AKT inhibition in luminal breast cancer
Inhibition of GPX4 enhances CDK4/6 inhibitor and endocrine therapy activity in breast cancer
MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer
Silencing CDK4 radiosensitizes breast cancer cells by promoting apoptosis
FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1
TEX19 increases the levels of CDK4 and promotes breast cancer by disrupting SKP2-mediated CDK4 ubiquitination
Position paper on CDK4/6 inhibitors in early breast cancer
Translational Highlights in Breast and Ovarian Cancer 2019 – Immunotherapy, DNA Repair, PI3K Inhibition and CDK4/6 Therapy
Inhibition of proliferation and migration of luminal and claudin-low breast cancer cells by PDGFR inhibitors
GRHL2-controlled gene expression networks in luminal breast cancer